Log in
Enquire now
Adverum Biotechnologies

Adverum Biotechnologies

Adverum is a gene therapy company committed to discovering and developing novel medicines to patients living with rare diseases and diseases of the eye.

OverviewStructured DataIssuesContributors

Contents

adverum.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Gene therapy
Gene therapy
Healthcare
Healthcare
Consumer biotechnology
Consumer biotechnology
Biomedical engineering
Biomedical engineering
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
...
Location
Redwood City, California
Redwood City, California
San Francisco
San Francisco
United States
United States
Menlo Park, California
Menlo Park, California
B2X
B2B
B2B
CEO
Leone Patterson
Leone Patterson
Founder
Mark S. Blumenkranz
Mark S. Blumenkranz
Mitchell H. Finer
Mitchell H. Finer
Pitchbook URL
pitchbook.com/profiles.../59995-99
Legal Name
Adverum Biotechnologies, Inc.
Legal classification
Corporation
Corporation
Date Incorporated
July 25, 2006
Number of Employees (Ranges)
51 – 200
Phone Number
+165065693230
Full Address
100 Cardinal Way, Redwood City, CA 940630
800 SAGINAW DRIVE, REDWOOD CITY, CA, 94063
CIK Number
1,501,7560
Place of Incorporation
Delaware
Delaware
0
Investors
Rock Springs Capital
Rock Springs Capital
IRS Number
205,258,3270
Founded Date
2012
0
Total Funding Amount (USD)
70,700,000
Latest Funding Round Date
September 2014
Competitors
Akouos
Akouos
Stock Symbol
ADVM0
Exchange
Nasdaq
Nasdaq
0
Glassdoor ID
1306210
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
2
Country
United States
United States

Other attributes

Company Operating Status
Active
Contact Page URL
adverum.com/contact-us/
Previous Name
Avalanche Biotechnologies, Inc.0
SIC Code
2,8360
Ticker Symbol
ADVM

Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.

Funding
Venture round I

On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors.

Series B

On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.

Venture round II

On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Avalanche Biotechnologies Agrees to Buy Annapurna Therapeutics

Genenews

https://www.genengnews.com/topics/drug-discovery/avalanche-biotechnologies-agrees-to-buy-annapurna-therapeutics/

Web

Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today

Maxx Chatsko

https://www.fool.com/investing/2018/11/02/heres-why-adverum-biotechnologies-dropped-as-much.aspx

Web

References

Find more companies like Adverum Biotechnologies

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.